Cencora, Inc. (NYSE:COR) Shares Acquired by IFP Advisors Inc

IFP Advisors Inc increased its stake in Cencora, Inc. (NYSE:COR) by 105.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,810 shares of the company’s stock after acquiring an additional 927 shares during the period. IFP Advisors Inc’s holdings in Cencora were worth $410,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of COR. JFS Wealth Advisors LLC increased its holdings in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares during the last quarter. Kentucky Trust Co purchased a new position in Cencora in the fourth quarter valued at $33,000. Householder Group Estate & Retirement Specialist LLC increased its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares during the last quarter. WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after buying an additional 46 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora in the third quarter valued at $41,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

COR has been the topic of several recent analyst reports. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Barclays raised their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Performance

Shares of COR stock opened at $253.49 on Friday. The stock has a market capitalization of $49.16 billion, a PE ratio of 36.06, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26. The stock’s 50-day moving average price is $241.71 and its 200 day moving average price is $237.84. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.